Fate Therapeutics, Inc. (FRA:F6T)

Germany flag Germany · Delayed Price · Currency is EUR
0.8962
+0.0580 (6.92%)
At close: Dec 4, 2025
-67.89%
Market Cap 108.81M
Revenue (ttm) 6.08M
Net Income (ttm) -133.04M
Shares Out n/a
EPS (ttm) -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 8
Open 0.8962
Previous Close 0.8382
Day's Range 0.8962 - 0.8962
52-Week Range 0.6004 - 2.5440
Beta n/a
RSI 46.39
Earnings Date Nov 20, 2025

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Employees 181
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol F6T
Full Company Profile

Financial Performance

In 2024, Fate Therapeutics's revenue was $13.63 million, a decrease of -78.55% compared to the previous year's $63.53 million. Losses were -$186.26 million, 15.7% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.